Angelini Pharma to Acquire Catalyst Pharmaceuticals for $4.1 Billion
Angelini Pharma has agreed to acquire Catalyst Pharmaceuticals in an all-cash transaction. The deal values Catalyst at $31.50 per share, with a total implied value of approximately $4.1 billion.
The boards of both companies unanimously approved the transaction. The deal is expected to close in the third quarter of 2026, pending stockholder approval and customary closing conditions.
Key Takeaways
- Angelini Pharma will acquire Catalyst Pharmaceuticals for $31.50 per share in cash.stocktitan.netangelinipharma.com
- The total transaction value is approximately $4.1 billion.angelinipharma.comir.catalystpharma.combiopharmadive.com
- The deal is expected to close in the third quarter of 2026.stocktitan.net
- Catalyst stockholders will vote on the merger on July 8, 2026.stocktitan.net
Sources
Catalyst Pharmaceuticals Inc Merger Proxy Statement
StockTitan
“Documents the $31.50 per share cash offer and the July 8, 2026 stockholder vote date.”
Angelini Pharma to Acquire Catalyst Pharmaceuticals
Catalyst Pharmaceuticals
“Confirms unanimous board approval for the $4.1 billion deal.”
Angelini Pharma to Acquire Catalyst Pharmaceuticals
Angelini Pharma
“Announces the $4.1 billion acquisition to enter the US market and lead in brain health.”